Results 21 to 30 of about 5,449 (190)

In vitro pharmacokinetics of cefiderocol alone and in combination with antibiotics against Achromobacter spp. and Stenotrophomonas maltophilia species

Journal of Global Antimicrobial Resistance
AIM: The point of this study was to compare and to contrast how well cefiderocol worked against a group of Achromobacter spp. and Stenotrophomonas maltophilia isolates in-vitro, both by itself and when mixed with other antibiotics.
Gokce Konyaoglu, Bekir Ozer, Bilge Sumbul, Mesut Yilmaz, Berna Ozbek Celik, Emel Mataraci Kara   +5 more
doaj   +2 more sources

Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study [PDF]

Infectious Diseases and Therapy
Introduction Cefiderocol is a siderophore cephalosporin showing activity against various carbapenem-resistant Gram-negative bacteria (CR-GNB). No data currently exist about real-world use of cefiderocol in terms of types of therapy (e.g., empirical or ...
Daniele Roberto Giacobbe, Laura Labate, Chiara Russo Artimagnella, Cristina Marelli, Alessio Signori, Vincenzo Di Pilato, Chiara Aldieri, Alessandra Bandera, Federica Briano, Bruno Cacopardo, Alessandra Calabresi, Federico Capra Marzani, Anna Carretta, Annamaria Cattelan, Luca Ceccarelli, Giovanni Cenderello, Silvia Corcione, Andrea Cortegiani, Rosario Cultrera, Francesco Giuseppe De Rosa, Valerio Del Bono, Filippo Del Puente, Chiara Fanelli, Fiorenza Fava, Daniela Francisci, Nicholas Geremia, Lucia Graziani, Andrea Lombardi, Angela Raffaella Losito, Ivana Maida, Andrea Marino, Maria Mazzitelli, Marco Merli, Roberta Monardo, Alessandra Mularoni, Chiara Oltolini, Carlo Pallotto, Emanuele Pontali, Francesca Raffaelli, Matteo Rinaldi, Marco Ripa, Teresa Antonia Santantonio, Francesco Saverio Serino, Michele Spinicci, Carlo Torti, Enrico Maria Trecarichi, Mario Tumbarello, Malgorzata Mikulska, Mauro Giacomini, Anna Marchese, Antonio Vena, Matteo Bassetti, CEFI-SITA investigators   +52 more
doaj   +6 more sources

Evolution of β-lactamase-mediated cefiderocol resistance [PDF]

, 2022
BACKGROUND: Cefiderocol is a novel siderophore β-lactam with improved hydrolytic stability toward β-lactamases, including carbapenemases, achieved by combining structural moieties of two clinically efficient cephalosporins, ceftazidime and cefepime ...
Fröhlich, Christopher, Sørum, Vidar, Frøhlich, Christopher, Tokuriki, Nobuhiko, Johnsen, Pål Jarle, Samuelsen, Ørjan   +5 more
core   +1 more source

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii [PDF]

, 2023
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Zarrilli R., Migliaccio A., Karruli A., Durante-Mangoni E., Pournaras S.   +4 more
core   +4 more sources

Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei [PDF]

, 2023
Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by β-lactam and multidrug-resistant Gram-negative bacteria.
Bart J., Currie, Herbert P., Schweizer, Carina M., Hall, Roxanne, Nottingham, Johannah P., Hagen, Mark, Mayo, Jessica R., Webb, Jason W., Sahl, Nawarat, Somprasong, Paul, Keim, Yuwana, Podin, David M., Wagner   +11 more
core   +1 more source

Disc Diffusion and ComASP® Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine [PDF]

, 2023
Cefiderocol susceptibility testing represents a major challenge for clinical microbiology. Although disc diffusion showed robustness to test cefiderocol susceptibility, large areas of technical uncertainty (ATU) are reported by current EUCAST breakpoints.
Gabriele Bianco, Boattini, Matteo, Matteo Boattini, Rossana Cavallo, Sara Comini, Cristina Costa, Comini, Sara, Costa, Cristina, Banche, Giuliana, Cavallo, Rossana, Giuliana Banche, Bianco, Gabriele   +11 more
core   +1 more source

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

Microbiology Spectrum, 2022
Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019).
James A. Karlowsky, Andrew J. Walkty, Melanie R. Baxter, Heather J. Adam, Philippe R. S. Lagacé-Wiens, Frank Schweizer, Denice Bay, Joseph P. Lynch, Michael R. Mulvey, George G. Zhanel   +9 more
doaj   +1 more source

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program

Microbiology Spectrum, 2022
Cefiderocol is a siderophore-conjugated cephalosporin with broad activity against Gram-negative (GN) bacteria, including carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa, Acinetobacter spp., and Stenotrophomonas maltophilia ...
Dee Shortridge, Jennifer M. Streit, Rodrigo Mendes, Mariana Castanheira   +3 more
doaj   +1 more source

Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway

Journal of Global Antimicrobial Resistance, 2023
: Here we report the in vivo development of cefiderocol resistance within 11 days after therapy initiation in a critically ill patient with bloodstream infection, infection of peri-anal fistula, and pneumonia caused by a VIM-2 harbouring, carbapenem ...
Luise Brakert, Laura Berneking, Anna Both, Benjamin Berinson, Jiabin Huang, Martin Aepfelbacher, Christine Wolschke, Dominic Wichmann, Holger Rohde   +8 more
doaj   +1 more source

In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014–2018

Journal of Global Antimicrobial Resistance, 2021
: Objectives: The prevalence of Gram-negative bacteria (GNB) demonstrating extensive, multiple antimicrobial resistance is increasing in England, leaving few treatment choices.
Vanya Gant, Abid Hussain, Malcolm Bain, Christopher Longshaw, Anne Santerre Henriksen   +4 more
doaj   +1 more source